Summary Analysis of bioactive substances produced by cancer cells is one approach to understanding the biological features of human cancer. One of these bioactive substances is endothelin (ET)-1, a peptide with potent vasoconstrictive activity produced by vascular endothelial cells. We have previously reported the production of ET-1 by several types of human cancer, especially pancreatic cancer cells. To elucidate whether these cancer cells might share biological characteristics with vascular endothelial cells, we investigated the production of three ET isoforms in pancreatic cancer cells, using a specific radioimmunoassay. Further, we also investigated whether these cells produce thrombomodulin (TM), another product of endothelial cells functioning as a modulator of procoagulant activity. ET-1 was detected in 11 of 12 pancreatic cancer cell lines (92%) while ET-2 and ET-3 were detectable in only one cell line. Gel filtration analysis confirmed the presence of ET-1. Moreover, TM was detected in the cell lysates of 11 of the 12 cell lines (92%) and it was released into the culture medium in the majority (58%) of these cell lines. TM mRNA was also detected in these cells. In addition, TM was demonstrated immunocytochemically along the cell surface. These results suggest that pancreatic cancer cells share two characteristics with endothelial cells: the production of ET-1 and TM.
Neoplastic cells frequently produce bioactive substances, such as hormones, cytokines and growth factors (Imanishi et al., 1989; Mori et al., 1991; Odell & Appleton, 1992) . These products have the potential to induce responses in remote target organs, normal tissues surrounding the cancer cells or the neoplastic cells themselves; these mechanisms of action are designated as endocrine, paracrine and autocrine respectively. One of these bioactive substances is endothelin (ET)-1, a peptide with potent vasoconstrictive activity produced by vascular endothelial cells (Yanagisawa et al., 1988) . We have previously reported the production of ET-1 by several types of human malignant cells, and raised the possibility that ET-1 produced by cancer cells stimulates cellular growth of stromal cells surrounding cancer cells in a paracrine fashion (Kusuhara et al., 1990) . This observation has been confirmed by other researchers (Schrey et al., 1992; Yamashita et al., 1992) .
The mechanism responsible for the ET-1 production by cancer cells is presently unknown. We have speculated that cancer cells producing ET-1 share biological characteristics with vascular endothelial cells. The present study was undertaken to explore this possibility. We focused on pancreatic cancer cells; among various types of malignant cells, pancreatic cancer cells produced ET-1 at the highest frequencies and largest quantities in a relatively small-scale study conducted previously (Kusuhara et al., 1990) . To confirm this first, we prepared 12 human pancreatic cancer cell lines. We investigated the production of three ET isoforms (Inoue et al., 1989) , ET-1, ET-2 and ET-3, to determine whether the patterns of expression of ET isoforms were similar to that of endothelial cells. Furthermore, we examined whether these cells produced thrombomodulin (TM), which is a modulator of the coagulation cascade and is predominantly produced in endothelial cells (Esmon et al., 1982; Maruyama et al., 1985) . Cell culture Sixteen human malignant cell lines were examined. These were 12 pancreatic cancer cell lines (ASPC-1, BxPC-3, FA-6, MIAPaCa-2, PANC-1, PSN-1, KP1N, KP2, KP3, H48N, CAPAN-1 and CAPAN-2), a gastric cancer cell line (MKN-28), a lung cancer cell line (A-549), a melanoma cell line (SEKI) and an acute promyelocytic leukaemia cell line (HL-60). Of these, PSN-1 and SEKI were established at the National Cancer Center Research Institute (Tokyo, Japan) (Shimoyama, 1975; Yamada et al., 1986 ). FA-6 was a gift from N. Nagata (National Defense Medical College, Saitama, Japan) (Nagata et al., 1989) . KP1N, KP2, KP3, H48N were established by A. Kono and colleagues (National Kyushu Cancer Center, Fukuoka, Japan) (Ikeda et al., 1990) .
Materials and methods

Materials
MKN-28 was kindly provided by H. Watanabe (Niigata University School of Medicine, Niigata, Japan) (Motoyama et al., 1986) . The other cell lines were purchased from the American Type Culture Collection (Rockville, MD, USA). As for the pancreatic cancer cell lines, the histopathology of the original tumours is given in Tables I and II (CBI, Saclay, France) for CA19-9, CEA RIABEAD kit (Dainabot, Tokyo, Japan) for CEA and DUPAN-2 EIA kit (Kyowa Medix, Tokyo, Japan) for DUPAN-2. For the DUPAN-2 EIA kit, the inter-and intra-assay coefficients of variation (CVs) at a concentration of 400 U ml1' were 5.01% (n = 5) and 2.65% (n = 10) respectively. The limit of detectability of the three kits was 10 U ml-', 0.5 ng ml-' and 25 U ml-' respectively.
Radioimmunoassay for ET-J, ET-2 and ET-3 Extracton of the spent media and radioimmunoassay for ET-1 was performed by the previously established method (Kusuhara et al., 1990) . The procedures for ET-2 and ET-3 will be reported elsewhere (M. Kusuhara et al., manuscript in preparation). Briefly, the spent medium (20 ml) retained on the ODS cartridge was eluted with 80% acetonitrile in 0.1% trifluoroacetic acid, lyophilised and assayed. Fresh medium supplemented with 5% FCS was used as negative control. Synthetic ET-1, ET-2 or ET-3 conjugated to porcine thyroglobulin was emulsified with an equal volume of complete Freund's adjuvant and used for immunisation. Antisera obtained from immunised guinea pigs were specific for each ET isoform. In the ET-2 radioimmunoassay, the amount of ET-2 which inhibited labelled antigen binding by 50% was 10 fmol per tube. The inter-and intra-assay CVs at 20 fmol per tube were 8.0% (n = 8) and 5.0% (n = 10) respectively. When the cross-reactivity of ET-2 was taken to be 100%, the cross-reactivities of ET-1, big ET-1 and ET-3 were 0.003%, 0.008% and less than 0.002% respectively. For ET-3, the amount of ET-3 that inhibited the labelled antigen binding by 50% was 20 fmol per tube. The inter-and intra-assay CVs at 20 fmol per tube were 7.7% (n = 8) and 5.5% (n = 10) respectively. When the cross-reactivity of ET-3 was taken to be 100%, the cross-reactivities of ET-1, big ET-1 and ET-2 were less than 0.005%. In the present experimental conditions, the lowest detectable level of ET-1, ET-2 and ET-3 in the spent media was 2.5 pM, 2.5 pM and 5.0 pM respectively. The assay was performed in 0.1 M phosphate buffer pH 7.4, containing 0.1 M sodium chloride, 0.06% (v/v) monoethanolamine, 1% (w/v) disodium EDTA, 0.9% tetrasodium EDTA and 0.1% BSA. The synthetic peptides for the ET isoforms were used for the assay standards. After incubation formaldehyde-agarose gel, and transferred to Hybond-N (Amersham). Hybridisation was performed at 42°C for 20 h in hybridisation buffer containing 50% formamide and 0.8 M sodium chloride. Washing was performed three times with 2 x SSC containing 0.1% SDS at 50°C for 10 min. For detecting TM mRNA, an oligodeoxyribonucleotide was synthesised and used as the probe. Its sequence was 5'-CAC CGA GGA GCG CAC TGT CAT TAG GTG GCC CCG CAG TCC GTC GCA GAT CTG ACT GGC ATT-3', which is the anti-sense sequence for nucleotides 139-198 of TM (Suzuki et al., 1987) . It was labelled with [7y-32P]ATP and used at a concentration of about 5 x 106 c.p.m. ml-'. P-Actin mRNA running at about 2.0 kb was also examined to determine the integrity of these mRNA samples by the previously described method (Honda et al., 1988) .
Immunostaining procedure for thrombomodulin After cells grown in chamber slides were fixed with 10% buffered formalin for 1 h, the slides were rinsed with phosphate-buffered saline (PBS) containing 3% BSA for 30 min. TM was detected by the avidin-biotin-peroxidase method by using a monoclonal antibody, TMMAb2O (Ishii et al., 1990) , as a primary antibody. 
Gelfiltration studies
The gel filtration patterns of the extracts prepared from the spent media of two pancreatic cancer cell lines and HUVECs are shown in Figure 1 . The major peak was eluted at the position identical to that of synthetic Thrombomodulin in the cell lysates and in the spent media The concentrations of TM in the cell lysate and in the spent media are shown in Table II . Cell lysates prepared from 11 pancreatic cancer cell lines (92%) contained various amounts of TM ranging from 0.31 to 150 ng ml-10-6 cells. Furthermore, TM was also detected in the spent media of seven of those 11 cell lines (58%), especially in the cell lines containing relatively large amounts of TM in cell lysates. Only one cell line, MIAPaCa-2, which did not produce ET-1 either, did not produce a detectable amount of TM in its cell lysate. On the other hand, HUVECs expressed TM at a concentration of 18 ng ml-' 10-6 cells. TM was not detected in buffer containing detergent and in fresh medium supplemented with 5% FCS. Of the other malignant cell types, A-549 cells contained TM at a concentration of 0.45 ng ml' 10-6 cells, but TM was not detected in cell lysates of the other three cell lines (data not shown).
Expression of mRNA for thrombomodulin The autoradiogram of Northern blot analysis for TM mRNA in four pancreatic cancer cell lines is shown in Figure 2 . A band with a molecular size of approximately 4.3 kb was detected in the ASPC-1 and BxPC-3 cell lines, which produced large amounts of TM. In contrast, there was no band in FA-6 and MIAPaCa-2, which produced only a small or undetectable amount of TM. P-Actin mRNA was expressed
in all the cell lines tested.
Immunostaining for thrombomodulin Positive staining for TM was obtained in all 11 preparations of pancreatic cancer cells (92%) whose lysates contained amounts of TM detectable by enzyme immunoassay. Positive staining was limited to the cell surface. In contrast, specific staining was not detected in MIAPaCa-2 cells, in which TM 
Discussion
Twelve human pancreatic cancer cell lines were examined in the present study. We analysed the production and the release of three tumour markers in comparison to ET-1 and TM. CA19-9 and DUPAN-2 are relatively specific for pancreatic cancer, while CEA is not specific but is frequently produced by pancreatic cancer cells (Satake, 1991) . In this study, eight of the 12 cell lines were found to produce CA19-9, and several produced CEA or DUPAN-2 as well. The four remaining cell lines were characterised mainly by morphological analysis (Lieber et al., 1975; Yunis et al., 1977; Owens et al., 1979; Yamada et al., 1986; Ikeda et al., 1990) , which suggested that they originated from pancreatic cancer.
Using these pancreatic cancer cell lines, we confirmed our previous observation that ET-1 is frequently produced in human pancreatic cancer cell lines (Kusuhara et al., 1990) . Further research revealed that the human genome has two other DNA sequences similar to ET-1 (Inoue et al., 1989) , and these two putative peptides were termed ET-2 and Both are produced by several types of cells (Saida et al., 1989; MacCumber et al., 1990) (Kusuhara et al., 1990) : the production of ET-1.
We extended our study to determine whether another product of endothelial cells is produced by pancreatic cancer cell lines. TM is a membrane-bound glycoprotein with the ability to modulate blood coagulation (Esmon et al., 1982; Maruyama et al., 1985) , and it is dominantly expressed in endothelial cells and the placenta. The following results clearly demonstrate that human pancreatic cancer cells frequently produce TM. First, TM was detected by specific enzyme immunoassay in almost all pancreatic cancer cell lysates and in the majority of the spent media. It is worth noting that pancreatic cancer cells produce a considerable amount of TM compared with that produced by human umbilical vein endothelial cells. Second, TM was also detected immunocytochemically in these cells. All of the cell lines in which TM was detected by enzyme immunoassay showed positive staining for TM. The distribution pattern of TM was compatible with that in endothelial cells (Esmon et al., 1982; Maruyama et al., 1985) . Third, TM mRNA was expressed in two pancreatic cancer cell lines producing a large amount of TM. There are several studies on detection of TM in human primary tumours of vascular endothelial and syncytiotrophoblastic cell origin (Yonezawa et al., 1987 (Yonezawa et al., , 1988 , malignant pleural mesothelioma (Collins et al., 1992) and lung cancer (Tamura et al., 1993) . The fact that TM was detected in almost all pancreatic cancer cell lines suggests that TM could serve as a useful marker for primary human pancreatic carcinoma. Recent research also revealed increased plasma TM levels in pancreatic cancer patients (Lindahl et al., 1993) . Together with the possibility that it reflects coagulopathy often seen in pancreatic cancer patients, this phenomenon might be explained in part by the production of TM in pancreatic cancer tissue. This subject merits further investigation in the future.
The present study revealed that pancreatic cancer cells possess the biological characteristic of producing two products of endothelial cells, ET-1 and TM. Both ET-1 and TM were detected more frequently than tumour markers such as CA19-9, CEA and DUPAN-2. There seems to be no apparent correlation between ET-1 and/or TM production and the degree of differentiation of the tumours from which the cell lines were derived. Interestingly, placental syncytiotrophoblasts, which abundantly express TM as was the case for endothelial cells, do not produce ET-1 (Van Papendorp et al., 1991) . These facts raise the possibility that pancreatic cancer cells share some properties of vascular endothelial cells, rather than syncytiotrophoblasts. It might be that the pathological nature of pancreatic cancer cell growth, such as potent invasiveness (Furuta et al., 1992) , has some relationship to the mode of endothelial cell growth, which also seems to invade adjacent tissues (Furcht, 1986) . In this context, the characteristics of pancreatic cancer cells presented here might be useful in investigating the biology of pancreatic cancer in the future.
